Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1989 Jan 28;298(6668):235–238. doi: 10.1136/bmj.298.6668.235

Physical condition, longevity, and social performance of Dutch haemophiliacs, 1972-85.

C Smit 1, F R Rosendaal 1, I Varekamp 1, A Bröcker-Vriends 1, H Van Dijck 1, T P Suurmeijer 1, E Briët 1
PMCID: PMC1835514  PMID: 2493872

Abstract

A study was carried out among haemophiliacs in The Netherlands to evaluate the effect of modern substitution treatment (replacing the missing clotting factors) on medical and social performance. Three questionnaires were sent between 1972 and 1985. The use of prophylactic treatment in the group of patients with severe and moderately severe haemophilia increased from 21% (n = 242) in 1972 to 36% (n = 559) in 1985. Home treatment programmes increased from 4% to 53%. Overall mortality was 2.1 times higher than in the general male population, which leads to a calculated life expectancy of 66 years compared with 74 years in the general male population. Severe joint impairment was prominent in the older age groups, reflecting insufficient treatment in the past. A sharp decrease in the use of inpatient and outpatient hospital facilities was observed as well as much less absence from school and work. It is concluded that the high costs of modern substitution treatment are fully justified.

Full text

PDF
235

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aledort L. M. Lessons from hemophilia. N Engl J Med. 1982 Mar 11;306(10):607–608. doi: 10.1056/NEJM198203113061011. [DOI] [PubMed] [Google Scholar]
  2. Carter F., Forbes C. D., MacFarlane J. D., Prentice C. R. Cost of management of patients with haemophilia. Br Med J. 1976 Aug 21;2(6033):465–467. doi: 10.1136/bmj.2.6033.465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cash J. D. Coagulation factor VIII concentrates and the marketplace. Lancet. 1988 Jun 4;1(8597):1270–1270. doi: 10.1016/s0140-6736(88)92083-1. [DOI] [PubMed] [Google Scholar]
  4. Goedert J. J., Sarngadharan M. G., Eyster M. E., Weiss S. H., Bodner A. J., Gallo R. C., Blattner W. A. Antibodies reactive with human T cell leukemia viruses in the serum of hemophiliacs receiving factor VIII concentrate. Blood. 1985 Feb;65(2):492–495. [PubMed] [Google Scholar]
  5. Goldsmith M. F. Hemophilia, beaten on one front, is beset on others. JAMA. 1986 Dec 19;256(23):3200–3200. [PubMed] [Google Scholar]
  6. HAMMOND E. C., HORN D. Smoking and death rates; report on forty-four months of follow-up of 187,783 men. I. Total mortality. J Am Med Assoc. 1958 Mar 8;166(10):1159–1172. doi: 10.1001/jama.1958.02990100047009. [DOI] [PubMed] [Google Scholar]
  7. Johnson R. E., Lawrence D. N., Evatt B. L., Bregman D. J., Zyla L. D., Curran J. W., Aledort L. M., Eyster M. E., Brownstein A. P., Carman C. J. Acquired immunodeficiency syndrome among patients attending hemophilia treatment centers and mortality experience of hemophiliacs in the United States. Am J Epidemiol. 1985 Jun;121(6):797–810. doi: 10.1093/oxfordjournals.aje.a114051. [DOI] [PubMed] [Google Scholar]
  8. Larsson S. A. Life expectancy of Swedish haemophiliacs, 1831-1980. Br J Haematol. 1985 Apr;59(4):593–602. doi: 10.1111/j.1365-2141.1985.tb07353.x. [DOI] [PubMed] [Google Scholar]
  9. Lazerson J. Hemophilia home transfusion program: analysis of cost data. J Pediatr. 1973 Oct;83(4):623–625. doi: 10.1016/s0022-3476(73)80225-2. [DOI] [PubMed] [Google Scholar]
  10. Rosendaal F. R., Smit C., Varekamp I., Bröcker-Vriends A., Suurmeijer T. P., Briët E. AIDS and haemophilia. A study among Dutch haemophiliacs on the psychological impact of the AIDS threat, the prevalence of HIV antibodies and the adoption of measures to prevent HIV transmission. Haemostasis. 1988;18(2):73–82. doi: 10.1159/000215786. [DOI] [PubMed] [Google Scholar]
  11. Rouzioux C., Brun-Vezinet F., Couroucé A. M., Gazengel C., Vergoz D., Desmyter J., Vermylen J., Vermylen C., Klatzmann D., Geroldi D. Immunoglobulin G antibodies to lymphadenopathy-associated virus in differently treated French and Belgian hemophiliacs. Ann Intern Med. 1985 Apr;102(4):476–479. doi: 10.7326/0003-4819-102-4-476. [DOI] [PubMed] [Google Scholar]
  12. Smith P. S., Keyes N. C., Forman E. N. Socioeconomic evaluation of a state-funded comprehensive hemophilia-care program. N Engl J Med. 1982 Mar 11;306(10):575–579. doi: 10.1056/NEJM198203113061004. [DOI] [PubMed] [Google Scholar]
  13. Stuart J., Forbes C. D., Jones P., Lane G., Rizza C. R., Wilkes S. Improving prospects for employment of the haemophiliac. Br Med J. 1980 May 10;280(6224):1169–1172. doi: 10.1136/bmj.280.6224.1169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Wolfs T. F., Breederveld C., Krone W. J., vd Hoek L., Bakker M., Smit L., Goudsmit J. HIV-antibody seroconversions in Dutch haemophiliacs using heat-treated and non heat-treated coagulation factor concentrates. Thromb Haemost. 1988 Jun 16;59(3):396–399. [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES